Immune-resistant mechanisms in cancer immunotherapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Immune-resistant mechanisms in cancer immunotherapy

Published:2020-01-09 Issue:5 Volume:25 Page:810-817
ISSN:1341-9625
Container-title:International Journal of Clinical Oncology
language:en
Short-container-title:Int J Clin Oncol

Author:

Kawakami Yutaka,Ohta Shigeki,Sayem Mohammad A.,Tsukamoto Nobuo,Yaguchi Tomonori

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology,General Medicine,Surgery

Link

http://link.springer.com/content/pdf/10.1007/s10147-019-01611-x.pdf

Reference78 articles.

1. Couzin-Frankel J (2013) Breakthrough of the year 2013. Cancer immunotherapy. Science 342:1432–1433

2. Iwai Y, Ishida M, Tanaka Y et al (2002) Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 99:12293–12297

3. Topalian SL, Hodi FS, Brahmer JR et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443

4. Okazaki T, Chikuma S, Iwai Y et al (2013) Rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat Immunol 14:1212–1218

5. Yaguchi T, Kawakami Y (2016) Cancer-induced heterogeneous immunosuppressive tumor microenvironments and their personalized modulation. Int Immunol 28:393–399

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pt–Te–Nanorod-Based Photothermal Chemokine Immunotherapy for All Stages of Cancer via Adaptive and Innate Immunity;ACS Applied Materials & Interfaces;2024-07-15

2. Advancing non-small cell lung cancer treatment: the power of combination immunotherapies;Frontiers in Immunology;2024-07-02

3. Tumor eradication by triplet therapy with BRAF inhibitor, TLR 7 agonist, and PD‐1 antibody for BRAF‐mutated melanoma;Cancer Science;2024-06-18

4. Further knowledge and developments in resistance mechanisms to immune checkpoint inhibitors;Frontiers in Immunology;2024-06-05

5. CD155 Expression in Early-Stage Lung Adenocarcinoma;The Annals of Thoracic Surgery;2024-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3